J and J Snack Foods Newswire

J and J Snack Foods Newswire

Comprehensive Real-Time News Feed for J and J Snack Foods.

Results 1 - 20 of 1,394 in J and J Snack Foods

  1. J&J Snack Foods Corp. (JJSF) Shares Gap Up to $121.33Read the original story w/Photo

    7 hrs ago | Daily Political

    J&J Snack Foods Corp. shares gapped up before the market opened on Friday . The stock had previously closed at $121.17, but opened at $121.33.


  2. Kennedy Capital Management Inc. Sells 648 Shares of J&J Snack Foods Corp.Read the original story w/Photo

    13 hrs ago | Daily Political

    Kennedy Capital Management Inc. lowered its stake in shares of J&J Snack Foods Corp. by 2.6% during the first quarter, Holdings Channel reports. The firm owned 24,761 shares of the company's stock after selling 648 shares during the period.


  3. Global Erythropoietin Drugs Market 2016: Industry Demand, Segment, Statistics and Research to 2020Read the original story w/Photo

    16 hrs ago | SBWire

    Erythropoietin is a glycoprotein hormone synthesized in the bone marrow that controls and regulates the mechanism of erythropoiesis . These erythropoietin drugs are used for treatment of chemotherapy-induced anemia; anemia is a common side-effect occurring due to chemotherapy of End Stage Renal Diseases , cancer and HIV.


  4. J&J Snack Foods Corp. (JJSF) Set to Announce Earnings on MondayRead the original story w/Photo

    18 hrs ago | Daily Political

    J&J Snack Foods Corp. last posted its quarterly earnings results on Monday, April 25th. The company reported $0.83 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $0.78 by $0.05.


  5. J&J unit Acclarent to pay $18 million to settle false claims caseRead the original story

    19 hrs ago | WTAQ-AM Green Bay

    Johnson & Johnson Inc subsidiary Acclarent Inc., a California-based medical device manufacturer, has agreed to pay $18 million to resolve allegations that it caused healthcare providers to submit false claims to Medicare and other federal healthcare programs, the Justice Department said on Friday.


  6. J&J unit's former execs convicted of unapproved marketingRead the original story w/Photo

    Thursday | Star Tribune

    Two former executives of medical device company Acclarent, including one man from Minnesota, were convicted by a federal jury Wednesday on misdemeanor charges of promoting a health care product for an unapproved use. The executives were acquitted of similar felony charges.


  7. US investor buys J&J's opiate API business and announces restructuringRead the original story w/Photo

    Thursday | In-PharmaTechnologist.com

    SK Capital has rejigged the senior teams at opiate API maker Noramco and raw material supplier Tasmanian Alkaloids just weeks after buying the firms from Johnson & Johnson . The US private investment announced the changes today, explaining that Matthew Martin, previously the General Manager of both businesses, has been appointed as Noramco CEO.


  8. Acclarent's Relieva Scout Sinus Dilator Now Available in U.S.Read the original story w/Photo

    Thursday | Medgadget

    Acclarent , a J&J firm, is releasing in the U.S. its RELIEVA SCOUT multi-sinus dilation system, a balloon sinuplasty device for widening the sinus openings in people with chronic sinusitis. The device uses a flexible balloon that reaches a bit further out from the tip to be able to get deeper into the anatomy.


  9. These 5 Healthcare Stocks Have Huge Dividend Yields -- Are Any Worth Buying?Read the original story w/Photo

    Thursday | The Motley Fool

    Most investors love to buy stocks that pay dividends, and it's not hard to figure out why. In today's low-interest-rate environment, millions are forced to invest in dividend-paying stocks to generate any sort of yield on their nest egg.


  10. Johnson & Johnson Keeps Growing On Pharma StrengthRead the original story

    Wednesday Jul 20 | BioSpace

    Healthcare giant Johnson & Johnson has been a household name for decades, with mainstays like Band-Aid and Tylenol helping to drive consumer awareness of the company's extensive product list. Yet the consumer segment is now Johnson & Johnson's smallest in terms of sales, and the conglomerate's efforts to expand in the pharmaceutical and medical device arena have been vital to the company's overall success.


  11. Johnson & Johnson's Big Talcum Powder Cover UpRead the original story w/Photo

    Wednesday Jul 20 | Personal Injury News

    We are learning more and more about the dangers of Johnson & Johnson's talcum powder and the link between the company's talcum powder products and ovarian cancer. But, with more lawsuits being filed , we are also learning that Johnson & Johnson specifically marketed the products to low-income Americans and minorities despite knowing about the risks the products pose.


  12. UPDATE 1-J&J unit's former execs convicted of unapproved marketingRead the original story w/Photo

    Wednesday Jul 20 | Reuters

    Two former executives of Acclarent Inc, a medical device company bought by Johnson & Johnson in 2010, were convicted on Wednesday by a U.S. jury on charges of promoting a product for an unapproved use. Former Acclarent Chief Executive William Facteau and former Vice President of Sales Patrick Fabian were found guilty in federal court in Boston of 10 misdemeanor counts of violating the U.S. Food, Drug and Cosmetic Act, federal prosecutors said in a statement.


  13. Here's what the future of HIV treatment looks likeRead the original story w/Photo

    Wednesday Jul 20 | Silicon Alley Insider

    Now medical advances have made HIV, especially if diagnosed early, a disease that can be controlled with medication. But there's still a long way to go.


  14. P&G Just Missed an OpportunityRead the original story w/Photo

    Wednesday Jul 20 | Bloomberg

    Shelly Banjo is a Bloomberg Gadfly columnist covering retail and consumer goods. She previously was a reporter at Quartz and the Wall Street Journal.


  15. 3 Compelling Reasons to Buy Johnson & Johnson Following EarningsRead the original story w/Photo

    Wednesday Jul 20 | TheStreet.com

    This health and drug giant is the best in its class. Here is why investors need to load up on J&J stock, which won't disappoint over the long run.


  16. Johnson & Johnson: Great Earnings, And The Stock Is Cheaper Than It LooksRead the original story w/Photo

    Tuesday Jul 19 | Seeking Alpha

    J&J is a blue-chip company with a long history of steady earnings growth and reliable dividends. It has continued to rally over the past five years.


  17. S&P 500 Retreats From All-Time High as Corporate Earnings WeighRead the original story

    Tuesday Jul 19 | The Washington Post

    The S&P 500 Index slipped from a record as investors were circumspect on the prospects for further gains following a mix of corporate earnings reports. The recent record run for equities hit some headwinds as Netflix Inc. tumbled 14 percent after subscriber growth disappointed, and Philip Morris International Inc. dropped 3 percent after its earnings missed forecasts as the strong dollar hurt sales outside of the U.S. Johnson & Johnson provided some offset, climbing 1.5 percent after its quarterly profit beat estimates.


  18. J&J Cfo - Agnostic' on Size of M&a, Looks at Deals in All AreasRead the original story

    Tuesday Jul 19 | The Washington Post

    Johnson & Johnson will consider deals of any size and for any of its three main businesses, chief financial officer Dominic Caruso said, though when it comes to pharmaceuticals the company is more interested in less-risky licensing agreements. "We're equally interested in all three of our businesses," Caruso said in an interview with Bloomberg News.


  19. Wall Street moves lower on mixed earnings reportsRead the original story w/Photo

    Tuesday Jul 19 | Channelnewsasia.com

    U.S. stocks ticked lower on Tuesday as mixed earnings reports dented investor optimism entering the earnings season, while lower expectations of global growth also weighed on sentiment. Traders work on the floor of the New York Stock Exchange in New York City, U.S., July 19, 2016.


  20. Stocks Modestly Lower After Tech EarningsRead the original story

    Tuesday Jul 19 | Morningstar

    Housing starts rose a larger-than-expected 4.8% in June from the previous months. Building permits were up 1.5%.